COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR’s lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in humans in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions.

Immune-related diseases are more prevalent than ever in populations around the globe, yet they remain the hardest diseases to treat. These life-threatening illnesses, including autoimmune diseases such as multiple sclerosis and celiac disease, along with allergic diseases like peanut allergy, comprise a market larger than the entirety of cancer.

Immune therapies in use today are at best primitive. They rely on highly toxic immune suppression, shutting down the basic immune apparatus, often leading to significant untoward collateral immune disease. This approach does nothing to address the underlying cause of immune-related disease. Current medications offer only a modicum of symptomatic relief.

Scientists in immunology have posited that the gold standard for treating immune-related disease is tolerance – getting the body to recognize and tolerate the specific antigens or allergens that trigger destructive and often life-threatening immune activation.  While many researchers and companies have tried to create a model of tolerance therapy, none have succeeded in translating their approach to human clinical results – until COUR.

Based upon decades of research from the Stephen D. Miller Lab at Northwestern University, in combination with COUR’s breakthrough techniques in nanoparticle science, there is now a platform to address antigen/allergen specific immune mediated diseases.  An alternative to suppressing the immune system now exists creating the opportunity to reprogram it, and reverse the course of immune mediated disease – providing new hope to tens of millions of patients.